Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,662 public trials 323 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

NCT02164071

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Bronchial Diseases, +31 more
Locations
  • Hospital Txagorritxu Vitoria-Gasteiz, Alava, Spain
  • Hospital Sant Joan de Deu Espluges de Llobregat, Barcelona, Spain
  • Hospital Duran I Reynals L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Parc Tauli Sabadell, Barcelona, Spain
View all 22 locations
View Trial Details
Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

NCT00452569

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Clinic of Haematology, University Multiprofiled Hospital for Active Treatment "G. Stranski" Pleven, Bulgaria
  • Clinic of Haematology, University Multiprofiled Hospital for Active Treatment Plovdiv, Bulgaria
  • University of Multiprofiled Hospital for Active Treatment "Alexandrovska" - Sofia Sofia, Bulgaria
  • Military Medical Academy/Dept Haematology and Oncology Sofia, Bulgaria
View all 86 locations
View Trial Details
Completed

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

NCT00044018

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • H Lee Moffit Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • St Vincent's Cancer Center New York, United States
View Trial Details
Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Palo Verde Hematology Oncology Glendale, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
  • Providence St. Joseph Medical Center/Cancer Center Burbank, California, United States
View all 26 locations
View Trial Details
Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

NCT01568294

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • Tokai University Hospital Isehara, Kanagawa, Japan
  • Saitama Medical Center, Saitama Medical University Kawagoe, Saitama, Japan
  • National Cancer Center Hospital Tyuuou, Tokyo, Japan
View Trial Details
Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

NCT02348528

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Peking University Third Hospital Beijing, China
  • Peking Union Medical College Hospital Beijing, China
  • The 301 Hospital-Chinese PLA General Hospital Beijing, China
  • Xiangya Hospital of Central South University Changsha, China
View Trial Details
Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

NCT00555100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • National Hospital Organization Nagoya Medical Center Nagoya, Aichi-ken, Japan
  • Jichi Medical University Hospital Shimotsuke, Tochigi, Japan
  • Niigata Cancer Center Hospital Niigata, Japan
View Trial Details

Related conditions